Maladie de Sneddon-Wilkinson échappant à l'infliximab et à l'étanercept : efficacité de l'adalimumab

Our case confirms the previously reported dramatic efficacy of anti-TNF biological agents in recalcitrant SWD but highlights the possibility of subsequent loss of response. Furthermore, it illustrates the efficacy of adalimumab in this indication.